Stayble Therapeutics AB Cash Flow-to-Debt Ratio
Stayble Therapeutics AB cash flow-to-debt ratio. Stayble Therapeutics AB (STABL) has a Cash Flow-to-Debt Ratio of -0.79x as of December 2025, meaning its operating cash flow of Skr-1.34 Million could theoretically repay -1% of its total liabilities (Skr1.70 Million) in one year. See Stayble Therapeutics AB leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Stayble Therapeutics AB (2016–2025)
Cash flow-to-debt ratio of Stayble Therapeutics AB from 2016 to 2025. Historical debt coverage capacity for Stayble Therapeutics AB across 10 annual periods. Check STABL total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Stayble Therapeutics AB Cash Flow-to-Debt Ratio by Year (2016–2025)
Stayble Therapeutics AB cash flow-to-debt ratio by year from 2016 to 2025. Year-by-year debt coverage analysis for Stayble Therapeutics AB. For the full cash flow conversion analysis, see STABL cash generation efficiency.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.96x | Skr-6.72 Million | Skr1.70 Million | ▲ +35.7% |
| 2024 | -6.15x | Skr-14.67 Million | Skr2.38 Million | ▼ -35.8% |
| 2023 | -4.53x | Skr-23.54 Million | Skr5.19 Million | ▲ +29.6% |
| 2022 | -6.44x | Skr-24.89 Million | Skr3.87 Million | ▼ -156.0% |
| 2021 | -2.51x | Skr-9.63 Million | Skr3.83 Million | ▲ +74.3% |
| 2020 | -9.80x | Skr-23.98 Million | Skr2.45 Million | ▼ -33999.6% |
| 2019 | 0.03x | Skr289.39K | Skr10.01 Million | ▲ +101.0% |
| 2018 | -2.87x | Skr-5.42 Million | Skr1.89 Million | ▼ -32.9% |
| 2017 | -2.16x | Skr-2.62 Million | Skr1.21 Million | ▼ -70.5% |
| 2016 | -1.27x | Skr-1.39 Million | Skr1.10 Million | — |